What is Genome Medical?
Headquartered in South San Francisco, Genome Medical operates as a comprehensive telehealth platform dedicated to the promotion and delivery of clinical health services. The company specializes in providing professional health-related education and administrative support, utilizing a robust digital framework to facilitate remote consultations. By positioning itself at the intersection of precision medicine and accessible healthcare, the firm addresses critical gaps in the current medical delivery system, ensuring that patients and providers can collaborate seamlessly regardless of geographic constraints.
How much funding has Genome Medical raised?
Genome Medical has raised a total of $120M across 3 funding rounds:
Series A
$23M
Series B
$37M
Series C
$60M
Series A (2017): $23M with participation from Canaan Partners, HealthInvest Equity Partners, Illumina Ventures, and Flywheel Ventures
Series B (2020): $37M led by Perceptive Advisors, Dreamers Fund, Canaan Partners, Manatt Venture Fund, Randy Scott, Casdin Capital, Samsung Electronics America, Kaiser Permanente Ventures, LRVHealth, Avestria Ventures, Echo Health Ventures, Revelation Partners, HealthInvest Equity Partners, Illumina Ventures, Flywheel Ventures, and GE Ventures
Series C (2021): $60M supported by Amgen Ventures, Canaan Partners, Casdin Capital, GV, Kaiser Permanente Ventures, and Perceptive Advisors
Key Investors in Genome Medical
Canaan Partners
Canaan Partners is a venture capital firm specializing in early-stage investments across technology and healthcare, with a strong focus on digital health and biopharma innovation.
Casdin Capital
Casdin Capital is an investment firm that brings deep expertise to the life sciences sector, specifically targeting diagnostics and molecular information pioneers.
Kaiser Permanente Ventures
Kaiser Permanente Ventures is a strategic investment arm focused on advancing healthcare innovation by partnering with entrepreneurs to build solutions that provide clear value for providers and patients.
What's next for Genome Medical?
Looking ahead, the strategic deployment of $60M is expected to accelerate the scaling of Genome Medical's clinical operations and technological capabilities. As the firm continues to mature, the focus will likely shift toward deepening its integration within established healthcare delivery systems and expanding its footprint in the genomics sector. The continued support from institutional partners suggests a long-term commitment to driving systemic healthcare transformation, with an emphasis on sustainable growth and the widespread adoption of precision health solutions in both clinical and research environments.
See full Genome Medical company page